182 related articles for article (PubMed ID: 34593984)
1. Predicting high-grade prostate cancer at initial biopsy: clinical performance of the ExoDx (EPI) Prostate Intelliscore test in three independent prospective studies.
Margolis E; Brown G; Partin A; Carter B; McKiernan J; Tutrone R; Torkler P; Fischer C; Tadigotla V; Noerholm M; Donovan MJ; Skog J
Prostate Cancer Prostatic Dis; 2022 Feb; 25(2):296-301. PubMed ID: 34593984
[TBL] [Abstract][Full Text] [Related]
2. A Prospective Adaptive Utility Trial to Validate Performance of a Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer in Patients with Prostate-specific Antigen 2-10ng/ml at Initial Biopsy.
McKiernan J; Donovan MJ; Margolis E; Partin A; Carter B; Brown G; Torkler P; Noerholm M; Skog J; Shore N; Andriole G; Thompson I; Carroll P
Eur Urol; 2018 Dec; 74(6):731-738. PubMed ID: 30237023
[TBL] [Abstract][Full Text] [Related]
3. Pre-diagnosis urine exosomal RNA (ExoDx EPI score) is associated with post-prostatectomy pathology outcome.
Kretschmer A; Tutrone R; Alter J; Berg E; Fischer C; Kumar S; Torkler P; Tadigotla V; Donovan M; Sant G; Skog J; Noerholm M
World J Urol; 2022 Apr; 40(4):983-989. PubMed ID: 35084544
[TBL] [Abstract][Full Text] [Related]
4. A urine-based Exosomal gene expression test stratifies risk of high-grade prostate Cancer in men with prior negative prostate biopsy undergoing repeat biopsy.
McKiernan J; Noerholm M; Tadigotla V; Kumar S; Torkler P; Sant G; Alter J; Donovan MJ; Skog J
BMC Urol; 2020 Sep; 20(1):138. PubMed ID: 32873277
[TBL] [Abstract][Full Text] [Related]
5. A Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer at Initial Biopsy.
McKiernan J; Donovan MJ; O'Neill V; Bentink S; Noerholm M; Belzer S; Skog J; Kattan MW; Partin A; Andriole G; Brown G; Wei JT; Thompson IM; Carroll P
JAMA Oncol; 2016 Jul; 2(7):882-9. PubMed ID: 27032035
[TBL] [Abstract][Full Text] [Related]
6. Clinical utility of the exosome based ExoDx Prostate(IntelliScore) EPI test in men presenting for initial Biopsy with a PSA 2-10 ng/mL.
Tutrone R; Donovan MJ; Torkler P; Tadigotla V; McLain T; Noerholm M; Skog J; McKiernan J
Prostate Cancer Prostatic Dis; 2020 Dec; 23(4):607-614. PubMed ID: 32382078
[TBL] [Abstract][Full Text] [Related]
7. Validation of a CE-IVD, urine exosomal RNA expression assay for risk assessment of prostate cancer prior to biopsy.
Kretschmer A; Kajau H; Margolis E; Tutrone R; Grimm T; Trottmann M; Stief C; Stoll G; Fischer CA; Flinspach C; Albrecht A; Meyer L; Priewasser T; Enderle D; Müller R; Torkler P; Alter J; Skog J; Noerholm M
Sci Rep; 2022 Mar; 12(1):4777. PubMed ID: 35314720
[TBL] [Abstract][Full Text] [Related]
8. ExoDx prostate test as a predictor of outcomes of high-grade prostate cancer - an interim analysis.
Tutrone R; Lowentritt B; Neuman B; Donovan MJ; Hallmark E; Cole TJ; Yao Y; Biesecker C; Kumar S; Verma V; Sant GR; Alter J; Skog J
Prostate Cancer Prostatic Dis; 2023 Sep; 26(3):596-601. PubMed ID: 37193776
[TBL] [Abstract][Full Text] [Related]
9. A Preliminary Study of the Ability of the 4Kscore test, the Prostate Cancer Prevention Trial-Risk Calculator and the European Research Screening Prostate-Risk Calculator for Predicting High-Grade Prostate Cancer.
Borque-Fernando Á; Esteban-Escaño LM; Rubio-Briones J; Lou-Mercadé AC; García-Ruiz R; Tejero-Sánchez A; Muñoz-Rivero MV; Cabañuz-Plo T; Alfaro-Torres J; Marquina-Ibáñez IM; Hakim-Alonso S; Mejía-Urbáez E; Gil-Fabra J; Gil-Martínez P; Ávarez-Alegret R; Sanz G; Gil-Sanz MJ
Actas Urol Esp; 2016 Apr; 40(3):155-63. PubMed ID: 26598800
[TBL] [Abstract][Full Text] [Related]
10. Utility of noninvasive biomarker testing and MRI to predict a prostate cancer diagnosis.
Sultan MI; Huynh LM; Kamil S; Abdelaziz A; Hammad MA; Gin GE; Lee DI; Youssef RF
Int Urol Nephrol; 2024 Feb; 56(2):539-546. PubMed ID: 37742327
[TBL] [Abstract][Full Text] [Related]
11. Validation of a 2-gene mRNA urine test for the detection of ≥GG2 prostate cancer in an opportunistic screening population.
Rubio-Briones J; Borque-Fernando A; Esteban LM; Mascarós JM; Ramírez-Backhaus M; Casanova J; Collado A; Mir C; Gómez-Ferrer A; Wong A; Aragón F; Calatrava A; López-Guerrero JA; Groskopf J; Schalken J; Van Criekinge W; Domínguez-Escrig J
Prostate; 2020 May; 80(6):500-507. PubMed ID: 32077525
[TBL] [Abstract][Full Text] [Related]
12. Detection of High-grade Prostate Cancer Using a Urinary Molecular Biomarker-Based Risk Score.
Van Neste L; Hendriks RJ; Dijkstra S; Trooskens G; Cornel EB; Jannink SA; de Jong H; Hessels D; Smit FP; Melchers WJ; Leyten GH; de Reijke TM; Vergunst H; Kil P; Knipscheer BC; Hulsbergen-van de Kaa CA; Mulders PF; van Oort IM; Van Criekinge W; Schalken JA
Eur Urol; 2016 Nov; 70(5):740-748. PubMed ID: 27108162
[TBL] [Abstract][Full Text] [Related]
13. Prostate cancer risk prediction using the novel versions of the European Randomised Study for Screening of Prostate Cancer (ERSPC) and Prostate Cancer Prevention Trial (PCPT) risk calculators: independent validation and comparison in a contemporary European cohort.
Poyet C; Nieboer D; Bhindi B; Kulkarni GS; Wiederkehr C; Wettstein MS; Largo R; Wild P; Sulser T; Hermanns T
BJU Int; 2016 Mar; 117(3):401-8. PubMed ID: 26332503
[TBL] [Abstract][Full Text] [Related]
14. Comparison of risk calculators from the Prostate Cancer Prevention Trial and the European Randomized Study of Screening for Prostate Cancer in a contemporary Canadian cohort.
Trottier G; Roobol MJ; Lawrentschuk N; Boström PJ; Fernandes KA; Finelli A; Chadwick K; Evans A; van der Kwast TH; Toi A; Zlotta AR; Fleshner NE
BJU Int; 2011 Oct; 108(8 Pt 2):E237-44. PubMed ID: 21507190
[TBL] [Abstract][Full Text] [Related]
15. Combined Clinical Parameters and Multiparametric Magnetic Resonance Imaging for Advanced Risk Modeling of Prostate Cancer-Patient-tailored Risk Stratification Can Reduce Unnecessary Biopsies.
Radtke JP; Wiesenfarth M; Kesch C; Freitag MT; Alt CD; Celik K; Distler F; Roth W; Wieczorek K; Stock C; Duensing S; Roethke MC; Teber D; Schlemmer HP; Hohenfellner M; Bonekamp D; Hadaschik BA
Eur Urol; 2017 Dec; 72(6):888-896. PubMed ID: 28400169
[TBL] [Abstract][Full Text] [Related]
16. How I Use It: The Exosome Diagnostics (EPI) prostate cancer biomarker utility in urology and primary care.
Moul JW; Sant GR
Can J Urol; 2022 Aug; 29(4):11224-11230. PubMed ID: 35969726
[TBL] [Abstract][Full Text] [Related]
17. Establishment and prospective validation of an SUV
Jiao J; Kang F; Zhang J; Quan Z; Wen W; Zhao X; Ma S; Wu P; Yang F; Guo W; Yang X; Yuan J; Shi Y; Wang J; Qin W
Theranostics; 2021; 11(17):8396-8411. PubMed ID: 34373749
[No Abstract] [Full Text] [Related]
18. Prediction of Prostate Cancer: External Validation of the ERSPC Risk Calculator in a Contemporary Dutch Clinical Cohort.
Gayet M; Mannaerts CK; Nieboer D; Beerlage HP; Wijkstra H; Mulders PFA; Roobol MJ
Eur Urol Focus; 2018 Mar; 4(2):228-234. PubMed ID: 28753781
[TBL] [Abstract][Full Text] [Related]
19. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment.
Tomlins SA; Day JR; Lonigro RJ; Hovelson DH; Siddiqui J; Kunju LP; Dunn RL; Meyer S; Hodge P; Groskopf J; Wei JT; Chinnaiyan AM
Eur Urol; 2016 Jul; 70(1):45-53. PubMed ID: 25985884
[TBL] [Abstract][Full Text] [Related]
20. Enhancement of prostate cancer diagnosis by machine learning techniques: an algorithm development and validation study.
Chiu PK; Shen X; Wang G; Ho CL; Leung CH; Ng CF; Choi KS; Teoh JY
Prostate Cancer Prostatic Dis; 2022 Apr; 25(4):672-676. PubMed ID: 34267331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
